Nöromusküler Kavşağın İmmün Aracılı Hastalıkları ve Miyastenia Gravis

Elmqvıst D, Hofmann WW, Kugelberg J, Quastel DM. An electrophysıologıcal ınvestıgatıon of neuromuscular transmıssıon ın Myasthenıa Gravıs. J Physiol. 1964;174(3):417-434. doi:10.1113/jphysiol.1964.sp007495

Patrick, J. and Lindstrom, J. Autoimmune Response to Acetylcholine Receptors. Science, 1973;180, 871-872. http://dx.doi.org/10.1126/science.180.4088.871

Rodrigues E, Umeh E, Aishwarya, Navaratnarajah N, Cole A, Moy K. Incidence and prevalence of myasthenia gravis in the United States: A claims-based analysis. Muscle Nerve. 2024;69(2):166-171. doi:10.1002/mus.28006

Vissing J, Atula S, Savolainen M, et al. Epidemiology of myasthenia gravis in Denmark, Finland and Sweden: a population-based observational study. J Neurol Neurosurg Psychiatry. 2024;95(10):919-926. Published 2024 Sep 17. doi:10.1136/jnnp-2023-333097

Salari N, Fatahi B, Bartina Y, et al. Global prevalence of myasthenia gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021;19(1):516. Published 2021 Dec 20. doi:10.1186/s12967-021-03185-7

Mıllıchap JG, Dodge PR. Diagnosis and treatment of myasthenia gravis in infancy, childhood, and adolescence: a study of 51 patients. Neurology. 1960;10:1007-1014. doi:10.1212/wnl.10.11.1007

Chen J, Tian DC, Zhang C, et al. Incidence, mortality, and economic burden of myasthenia gravis in China: A nationwide population-based study. Lancet Reg Health West Pac. 2020;5:100063. Published 2020 Nov 27. doi:10.1016/j.lanwpc.2020.100063

Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30. Published 2019 May 2. doi:10.1038/s41572-019-0079-

Kordas G, Lagoumintzis G, Sideris S, Poulas K, Tzartos SJ. Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients [published correction appears in PLoS One. 2015;10(1):e0117673. doi: 10.1371/journal.pone.0117673

Morgan, B.P.; Chamberlain-Banoub, J.; Neal, J.W.; Song, W.; Mizuno, M.; Harris, C.L. The Membrane Attack Pathway of Complement Drives Pathology in Passively Induced Experimental Autoimmune Myasthenia Gravis in Mice. Clin. Exp. Immunol. 2006; 146, 294–302.

Hara, H.; Hayashi, K.; Ohta, K.; Itoh, N.; Nishitani, H.; Ohta, M. Detection and Characterization of Blocking-Type Anti-Acetylcholine Receptor Antibodies in Sera from Patients with Myasthenia Gravis. Clin. Chem.1993, 39, 2053–2057.

Wintzen, A.R.; Plomp, J.J.; Molenaar, P.C.; van Dijk, J.G.; van Kempen, G.T.; Vos, R.M.; Wokke, J.H.; Vincent, A. Acquired Slow-Channel Syndrome: A Form of Myasthenia Gravis with Prolonged Open Time of the Acetylcholine Receptor Channel. Ann. Neurol. 1998; 44, 657–664.

Koneczny, I.; Cossins, J.; Waters, P.; Beeson, D.; Vincent, A. MuSK Myasthenia Gravis IgG4 Disrupts the Interaction of LRP4 with MuSK but Both IgG4 and IgG1-3 Can Disperse Preformed Agrin-Independent AChR Clusters. PLoS ONE 2013; 8, e80695.

McConville J, Farrugia ME, Beeson D, et al. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann Neurol. 2004;55(4):580-584. doi:10.1002/ana.20061

Ohta K, Shigemoto K, Kubo S, et al. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology. 2004;62(11):2132-2133. doi:10.1212/01.wnl.0000129274.12702.92

Rivner, M.H.; Quarles, B.M.; Pan, J.; Yu, Z.; Howard, J.F.; Corse, A.; Dimachkie, M.M.; Jackson, C.; Vu, T.; Small, G.; et al. Clinical Features of LRP4 /Agrin-antibody–Positive Myasthenia Gravis: A Multicenter Study. Muscle Nerve 2020;62, 333–343.

Zhang, B.; Tzartos, J.S.; Belimezi, M.; Ragheb, S.; Bealmear, B.; Lewis, R.A.; Xiong, W.-C.; Lisak, R.P.; Tzartos, S.J.; Mei, L. Autoantibodies to Lipoprotein-Related Protein 4 in Patients with Double-Seronegative Myasthenia Gravis. Arch. Neurol. 2012; 69, 445–451.

Cortés-Vicente E, Gallardo E, Martínez MÁ, et al. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. JAMA Neurol. 2016;73(9):1099-1104. doi:10.1001/jamaneurol.2016.2032

Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023-1036. doi:10.1016/S1474-4422(15)00145-3

Niks EH, Kuks JB, Roep BO, et al. Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5. Neurology. 2006;66(11):1772-1774. doi:10.1212/01.wnl.0000218159.79769.5c

Tolosa E, Li W, Yasuda Y, et al. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Invest. 2003;112(4):517-526. doi:10.1172/JCI18028

Meraouna A, Cizeron-Clairac G, Panse RL, et al. The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis. Blood. 2006;108(2):432-440. doi:10.1182/blood-2005-06-2383

Berrih-Aknin S, Ruhlmann N, Bismuth J, et al. CCL21 overexpressed on lymphatic vessels drives thymic hyperplasia in myasthenia. Ann Neurol. 2009;66(4):521-531. doi:10.1002/ana.21628

Silvestri NJ, Barohn RJ, Wolfe GI. Acquired Disorders of the Neuromuscular Junction.Swaiman KF, Ashwal S, Ferriero DM, et al (eds). Swaimans’s Pediatric Neurology. 6.Ed. Edinburgh: Elsevier;2018.p.2462-2476

Werner P, Kiechl S, Löscher W, Poewe W, Willeit J. Distal myasthenia gravis frequency and clinical course in a large prospective series. Acta Neurol Scand. 2003;108(3):209-211. doi:10.1034/j.1600-0404.2003.00136.x

Berrouschot J, Baumann I, Kalischewski P, Sterker M, Schneider D. Therapy of myasthenic crisis. Crit Care Med. 1997;25(7):1228-1235. doi:10.1097/00003246-199707000-0002

Rabinstein AA, Mueller-Kronast N. Risk of extubation failure in patients with myasthenic crisis. Neurocrit Care. 2005;3(3):213-215. doi:10.1385/NCC:3:3:213

O'Riordan JI, Miller DH, Mottershead JP, Hirsch NP, Howard RS. The management and outcome of patients with myasthenia gravis treated acutely In a neurological intensive care unit. Eur J Neurol. 1998;5(2):137-142. doi:10.1046/j.1468-1331.1998.520137.x

Chaudhuri A, Behan PO. Myasthenic crisis. QJM. 2009;102(2):97-107. doi:10.1093/qjmed/hcn152

Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A. Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol. 2010;68(6):797-805. doi:10.1002/ana.22139

Kömür M, Okuyaz Ç. Akut nöromusküler hastalıkların yönetimi. Turkiye Klinikleri J Pediatr Sci 2018;14(1):99-104.

Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000;70(1):327-334. doi:10.1016/s0003-4975(00)01595-2

Koneczny I, Martinez-Martinez P, de Baets M. Myyasthenia gravis.In:Ratcliffe MJH (eds). Encylopedia of Immunobiology. Academic press, Oxford ,UK, 2016;5:168-179

Peragallo JH. Pediatric Myasthenia Gravis. Semin Pediatr Neurol. 2017;24(2):116-121. doi:10.1016/j.spen.2017.04.003

Larner AJ. The place of the ice pack test in the diagnosis of myasthenia gravis. Int J Clin Pract. 2004;58(9):887-888. doi:10.1111/j.1742-1241.2004.00053.x

Shelly S, Paul P, Bi H, et al. Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm. Neurology. 2020;95(22):e3002-e3011. doi:10.1212/WNL.0000000000010910

Vincent A, McConville J, Farrugia ME, et al. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci. 2003;998:324-335. doi:10.1196/annals.1254.036

Chan KH, Lachance DH, Harper CM, Lennon VA. Frequency of seronegativity in adult-acquired generalized myasthenia gravis. Muscle Nerve. 2007;36(5):651-658. doi:10.1002/mus.20854

Hanisch F, Eger K, Zierz S. MuSK-antibody positive pure ocular myasthenia gravis. J Neurol. 2006;253(5):659-660. doi:10.1007/s00415-005-0032-8

Ohta K, Shigemoto K, Kubo S, et al. MuSK antibodies in AChR Ab-seropositive MG vs AChR Ab-seronegative MG. Neurology. 2004;62(11):2132-2133. doi:10.1212/01.wnl.0000129274.12702.92

Rivner, M.H.; Quarles, B.M.; Pan, J.; Yu, Z.; Howard, J.F.; Corse, A.; Dimachkie, M.M.; Jackson, C.; Vu, T.; Small, G.; et al. Clinical Features of LRP4 /Agrin-antibody–Positive Myasthenia Gravis: A Multicenter Study. Muscle Nerve 2020; 62, 333–343.

Zhang, B.; Tzartos, J.S.; Belimezi, M.; Ragheb, S.; Bealmear, B.; Lewis, R.A.; Xiong, W.-C.; Lisak, R.P.; Tzartos, S.J.; Mei, L. Autoantibodies to Lipoprotein-Related Protein 4 in Patients with Double-Seronegative Myasthenia Gravis. Arch. Neurol. 2012; 69, 445–451.

AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome. Muscle Nerve. 2001;24(9):1239-1247. doi:10.1002/mus.1140

Morren JA, Levin KH, Shields RW. Diagnostic Accuracy of Single Fiber Electromyography for Myasthenia Gravis in Patients Followed Longitudinally. J Clin Neurophysiol. 2016;33(5):469-474. doi:10.1097/WNP.0000000000000285

Gilhus NE, Nacu A, Andersen JB, Owe JF. Myasthenia gravis and risks for comorbidity. Eur J Neurol. 2015;22(1):17-23. doi:10.1111/ene.12599

Bernard C, Frih H, Pasquet F, et al. Thymoma associated with autoimmune diseases: 85 cases and literature review. Autoimmun Rev. 2016;15(1):82-92. doi:10.1016/j.autrev.2015.09.005

Bastakoti S, Kunwar S, Poudel S, et al. Rituximab in the Management of Refractory Myasthenia Gravis and Variability of Its Efficacy in Anti-MuSK Positive and Anti-AChR Positive Myasthenia Gravis. Cureus. 2021;13(11):e19416. Published 2021 Nov 9. doi:10.7759/cureus.19416

Liew WK, Powell CA, Sloan SR, et al. Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis. JAMA Neurol. 2014;71(5):575-580. doi:10.1001/jamaneurol.2014.17